-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[PharmaNet Corporate News] WuXi AppTec, the leading CXO company, recently announced that the company plans to establish a R&D and production base in Singapore, and expects to invest a total of 2 billion Singapore dollars (about 43 billion US dollars) in the new base in the next ten yea.
buildi.
This will help the company continue to accelerate the process of pharmaceutical innovation for the benefit of patients around the wor.
The establishment of the new base will further expand the capabilities and scale of WuXi AppTec's integrated empowerment platform, and provide global partners with a full range of R&D and production servic.
Facing the future, the Singapore base will further consolidate WuXi AppTec's global operation network, and link with bases in Asia, Europe, North America and other places to meet the growing needs of customers and continuously strengthen communication and cooperation with global partne.
With its unique CRDMO (Contract Research, Development and Manufacturing) and CTDMO (Contract Testing, Development and Manufacturing) business models, WuXi AppTec can provide customers with high-quality services more flexibly, further empowering global partners to accelerate new drug development progress, bringing more breakthrough treatment options to patien.
It is reported that the total investment will be invested in stages in the next 10 years according to the company's business development nee.
According to the data, WuXi AppTec is an enterprise that provides integrated, end-to-end new drug R&D and production services for the global biopharmaceutical indust.
At present, the company has operation bases in Asia, Europe, North America and other plac.
Through its unique "CRDMO" and "CTDMO" business models, WuXi AppTec continuously lowers the R&D threshold, helps customers improve R&D efficiency, and brings more breakthrough treatment solutions to patien.
The service scope covers chemical drug R&D and production, biological Research, preclinical testing and clinical trial development, cell and gene therapy development, testing and producti.
According to the 2021 annual report, WuXi AppTec realized a revenue of 2902 billion yuan, a year-on-year increase of 35%; on the profit side, the company's profit in 2021 exceeded 5 billion yuan, a year-on-year growth rate of 7
In addition, according to the company's performance forecast for the first half of 2022, it is expected that 22H1 revenue will be 1756 billion yuan, a year-on-year increase of 652%, exceeding the company's previously announced 63%-65% upper limit; net profit is 636 billion yuan, a year-on-year increase of 72
Deducted non-net profit was 850 billion yuan, a year-on-year increase of 800%; the adjusted Non-IFRS net profit attributable to the parent was 301 billion yuan, a year-on-year increase of 76
From the perspective of income composition, in recent years, WuXi AppTec's international income has shown an upward trend year by year, from 609 billion yuan in 2017 to 139 billion yuan in 202In 2021, international revenue will further increase, reaching 1122 billion yuan, of which the company's international revenue accounted for 73% in the first half of the ye.
It is reported that the company's revenue share from overseas customers has fluctuated around 75% in the past five yea.
The reason why the company can achieve such a beautiful performance lies in its strong technical research and development strength and the support of a strong talent te.
In terms of R&D investment, WuXi AppTec's R&D expenses increased from 437 million yuan in 2018 to 693 million yuan in 202In the first half of 2021, the company's R&D expenditure reached 404 million yuan, accounting for 8% of operating inco.
In addition, over the past ten years, WuXi AppTec has built an international management team composed of scientific research and management elites from China, the United States, Japan, India and other countries, with nearly a thousand high-level academic papers and an average of 15 years Experience in international high-level pharmaceutical and medical device compani.
The company's R&D team has nearly 6,000 people, 70% of which are masters and doctors, including more than 400 returnee scientis.
It is an enterprise with the largest number of employees and scientists in China's pharmaceutical R&D service indust.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
buildi.
This will help the company continue to accelerate the process of pharmaceutical innovation for the benefit of patients around the wor.
The establishment of the new base will further expand the capabilities and scale of WuXi AppTec's integrated empowerment platform, and provide global partners with a full range of R&D and production servic.
Facing the future, the Singapore base will further consolidate WuXi AppTec's global operation network, and link with bases in Asia, Europe, North America and other places to meet the growing needs of customers and continuously strengthen communication and cooperation with global partne.
With its unique CRDMO (Contract Research, Development and Manufacturing) and CTDMO (Contract Testing, Development and Manufacturing) business models, WuXi AppTec can provide customers with high-quality services more flexibly, further empowering global partners to accelerate new drug development progress, bringing more breakthrough treatment options to patien.
It is reported that the total investment will be invested in stages in the next 10 years according to the company's business development nee.
According to the data, WuXi AppTec is an enterprise that provides integrated, end-to-end new drug R&D and production services for the global biopharmaceutical indust.
At present, the company has operation bases in Asia, Europe, North America and other plac.
Through its unique "CRDMO" and "CTDMO" business models, WuXi AppTec continuously lowers the R&D threshold, helps customers improve R&D efficiency, and brings more breakthrough treatment solutions to patien.
The service scope covers chemical drug R&D and production, biological Research, preclinical testing and clinical trial development, cell and gene therapy development, testing and producti.
According to the 2021 annual report, WuXi AppTec realized a revenue of 2902 billion yuan, a year-on-year increase of 35%; on the profit side, the company's profit in 2021 exceeded 5 billion yuan, a year-on-year growth rate of 7
In addition, according to the company's performance forecast for the first half of 2022, it is expected that 22H1 revenue will be 1756 billion yuan, a year-on-year increase of 652%, exceeding the company's previously announced 63%-65% upper limit; net profit is 636 billion yuan, a year-on-year increase of 72
Deducted non-net profit was 850 billion yuan, a year-on-year increase of 800%; the adjusted Non-IFRS net profit attributable to the parent was 301 billion yuan, a year-on-year increase of 76
From the perspective of income composition, in recent years, WuXi AppTec's international income has shown an upward trend year by year, from 609 billion yuan in 2017 to 139 billion yuan in 202In 2021, international revenue will further increase, reaching 1122 billion yuan, of which the company's international revenue accounted for 73% in the first half of the ye.
It is reported that the company's revenue share from overseas customers has fluctuated around 75% in the past five yea.
The reason why the company can achieve such a beautiful performance lies in its strong technical research and development strength and the support of a strong talent te.
In terms of R&D investment, WuXi AppTec's R&D expenses increased from 437 million yuan in 2018 to 693 million yuan in 202In the first half of 2021, the company's R&D expenditure reached 404 million yuan, accounting for 8% of operating inco.
In addition, over the past ten years, WuXi AppTec has built an international management team composed of scientific research and management elites from China, the United States, Japan, India and other countries, with nearly a thousand high-level academic papers and an average of 15 years Experience in international high-level pharmaceutical and medical device compani.
The company's R&D team has nearly 6,000 people, 70% of which are masters and doctors, including more than 400 returnee scientis.
It is an enterprise with the largest number of employees and scientists in China's pharmaceutical R&D service indust.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
